Three months after an FDA advisory committee voted to recommend six peptides for pharmacy compounding, the Department of Health and Human Services has acted on that vote. A policy signed by Health Secretary Robert F. Kennedy Jr. says HHS does not intend to take enforcement action against state-licensed pharmacies, federal facilities and licensed physicians that compound BPC-157, Epitalon, KPV, MOTS-c, Semax or TB-500, as long as they meet a list of conditions [1][2].
HHS issued the document on October 28 and published a notice of availability in the Federal Register on October 30 [1][2]. Public comments are open through November 13 [1].
This is the biggest change in peptide access since these compounds were restricted in 2023. It is also narrower than many headlines suggest.
What enforcement discretion means
The six peptides are still not on the FDA's 503A bulks list, and none of them is FDA approved [1]. Under the law, that means pharmacies are not allowed to compound them. Enforcement discretion is a statement that the government will choose not to act against compounders who follow the rules HHS has laid out.
That distinction has practical effects. The policy can be changed or withdrawn without a formal rulemaking process, and HHS says it "may revisit" the policy if a safety signal or product quality problem shows up [1]. For each peptide, the policy is meant to last until the FDA finishes rulemaking that either adds the peptide to the bulks list or excludes it [3].
The policy came from the HHS Office of the Secretary. FDA scientists had recommended against listing all six peptides before the July advisory committee meeting [4]. Emideltide, which the committee voted down, is not included. Our July coverage has the vote-by-vote breakdown.
The ten conditions
To fall under the policy, a compounder has to meet every condition [1][3]:
- The peptide must be one of the six listed in the policy's appendix.
- It must match the identity and route of administration set out in the appendix.
- The bulk ingredient must come from an FDA-registered facility with a valid certificate of analysis (COA).
- The original manufacturer must be FDA-registered and compliant with current good manufacturing practice.
- The compounder must report its peptide products, serious adverse events and quality problems to the FDA and to the states involved.
- The label must say "This is a compounded drug product. Not for resale."
- Each product can contain only one active ingredient.
- Oral products need documentation that the formulation is adequately absorbed in humans.
- The only delivery device allowed in or with the product is an FDA 510(k)-cleared syringe.
- Everything else must comply with federal drug law, including the requirement for a prescription for an individual patient.
The single-ingredient rule rules out blends, so a combined BPC-157 and TB-500 vial of the kind sold as a "wolverine stack" would fall outside the policy.
Routes and forms for each peptide
The appendix limits each peptide to specific forms and routes [3]:
| Peptide | Form covered | Routes covered |
|---|---|---|
| BPC-157 | Acetate | Subcutaneous or intramuscular injection, oral, topical |
| TB-500 | Acetate | Subcutaneous or intramuscular injection |
| MOTS-c | Acetate | Subcutaneous or intramuscular injection |
| Epitalon | Acetate | Subcutaneous or intramuscular injection, in intermittent courses |
| KPV | Acetate | Oral, topical |
| Semax | Free base | Intranasal |
A pharmacy that compounds injectable KPV, or BPC-157 in its free base form, would be outside the policy [3].
Tighter testing for the raw material
Sourcing gets the most detail. The policy sets testing expectations for each bulk peptide, covering identity, purity, potency and impurities [3]. The COA must name the original manufacturing site, and when material passes through a distributor or repacker, that company must document how it validated the manufacturer and its COA [3]. A basic "research grade" COA of the kind many online vendors post does not meet the standard [3].
HHS was open about its goal. The policy says the Secretary expects it to "discourage the continued, widespread use of certain research-use-only peptides supplied by foreign manufacturers that pose a safety risk to US patients" [1].
What it leaves out
- 503B outsourcing facilities. The policy covers 503A pharmacies, federal facilities and physicians. Large-scale outsourcing facilities are not included [3].
- Research-use-only sellers. The policy does not change the status of peptides sold "for research use." The FDA has continued to send warning letters to online vendors this year, as we covered in August.
- State rules. State pharmacy and medical boards can still set stricter requirements.
- Other peptides. Popular compounds such as CJC-1295, Ipamorelin and GHK-Cu injectables are not covered.
What this means for patients
If you have been using one of these six peptides, the most likely change over the coming months is a new legal option: a prescription filled by a 503A compounding pharmacy that meets the HHS conditions. Expect pharmacies to take time to line up compliant suppliers, given the sourcing and testing requirements.
Supporters see this as a way to move people away from unregulated vials toward pharmacy-made products with traceable ingredients. Critics point out that the underlying human evidence is still thin. FDA's own reviewers found no clinical studies in humans for some of these peptides, including MOTS-c and KPV [4]. Both points can be true at once.
We will track how pharmacies respond and update our peptide pages as compliant options appear.
Disclaimer: This article is for informational purposes only and does not constitute medical or legal advice. Regulatory policies can change quickly. Check current guidance and talk with a qualified healthcare provider before starting, stopping or changing any peptide therapy.
Sources
- Foley & Lardner. Peptides: HHS Announces Limited Enforcement Discretion for Compounding of Six Peptides. October 30, 2026.
- National Community Pharmacists Association. FDA grants enforcement discretion to compounding six peptides. October 29, 2026.
- U.S. Department of Health and Human Services. HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. Docket HHS-OASH-2026-0496. 91 FR 68526. October 30, 2026.
- Howard J. FDA advisers support easing restrictions on six peptides. Here's what those drugs are and what happens next. CNN. July 31, 2026.